Clinical - Cyclotek

National University of Singapore (NUS) Yong Loo Lin School of Medicine – Clinical Imaging Research Centre (CIRC) and Cyclotek Announce Strategic Collaboration to Strengthen Radiopharmaceutical Capability in Singapore and Across ASEAN

NUS Medicine’s Clinical Imaging Research Centre (CIRC), a leading academic centre for advanced biomedical imaging within the National University Health System (NUHS), and Cyclotek, one of Australia and New Zealand’s premier radiopharmaceutical manufacturers and distributors, today announced a strategic collaboration to enhance radiopharmaceutical development, clinical trials, and precision diagnostic capability across Singapore and the wider […]

Cyclotek and Duchembio announce APAC extension of the license agreement for [18F]FP-CIT for the diagnosis of neurodegenerative disorders

Building on Cyclotek’s original 2017 agreement with Duchembio Co. Ltd., Cyclotek now holds rights to commercialise [18F]FP-CIT in Australia, New Zealand, Singapore, Malaysia, Indonesia, India, and Vietnam. This expansion enhances access to a critical diagnostic tool for clinicians and patients throughout the Asia-Pacific region, where demand for advanced neuroimaging continues to grow. The updated license […]

Cyclotek Awarded CRC-P Round 16 Grant to Advance Nanobody-Based Theranostic Platform for Cancer

Cyclotek, Australia’s leading radiopharmaceutical CDMO, is proud to announce its successful application for a Cooperative Research Centres Projects (CRC-P) Round 16 grant, awarded by the Australian Government to support collaborative industry-led research that delivers commercial outcomes.

Cyclotek Enables First in Human Company-Sponsored Trial with Terbium-161 Radiopharmaceutical in Australia

Cyclotek is excited to announce a contract development and manufacturing agreement with Radiopharm Theranostics, to support the company’s first-in-human, Phase 1 trial of RAD 402, a novel terbium-161 (¹⁶¹Tb) radiolabelled monoclonal antibody for the treatment of prostate cancer. Cyclotek, a leading Contract Development and Manufacturing Organization (CDMO) in radiopharmaceuticals, has been supporting commercially sponsored clinical […]

First Tumorad Dose Administered in World First Clinical Trial

Cyclotek would like to extend our congratulations to the team at Spago Nanomedical AB on the first administration of Lu177-SN201, in a world first Phase I/IIa clinical trial. This milestone represents the culmination of years of international collaborative effort from the Spago Nanomedical team, and Cyclotek is both proud and humbled to participate as manufacturing […]

Cyclotek supplies FBB to a Monash University led study promising treatment for dementia

Cyclotek is delighted to be a part of the Monash University-led study to investigate the safety and tolerability of treatment with sodium selenate in patients with Behavioral variant Frontotemporal Dementia (bvFTD), and to evaluate measures of efficacy to inform future Randomized-Controlled Trials (RCT) of sodium selenate in patients with bvFTD. The trial, led by Dr […]

Cyclotek announces the CRIB Project at Bio21

Cyclotek and the University of Melbourne’s Bio21 Institute are pleased to announce a significant collaboration into the development of radiopharmaceuticals for their Australian and Global partners. This initiative enables Cyclotek to establish a designated radiopharmaceutical research and development laboratory within the Bio21 Institute. The new lab demonstrates capabilities to engage with radionuclides that are garnering […]

Category: Clinical